What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Immune system
- Antibody
Falk Hiepe mainly focuses on Immunology, Antibody, Internal medicine, Lupus erythematosus and Bone marrow.
His Immunology and Plasma cell, Autoantibody, Autoimmune disease, Immune system and Autoimmunity investigations all form part of his Immunology research activities.
Falk Hiepe is involved in the study of Antibody that focuses on Connective tissue disease in particular.
His studies deal with areas such as Gastroenterology, Endocrinology and Surgery as well as Internal medicine.
He has researched Lupus erythematosus in several fields, including B cell and Monoclonal.
His Bone marrow research is multidisciplinary, incorporating perspectives in Immunoglobulin G and Homeostasis.
His most cited work include:
- Competence and competition: the challenge of becoming a long-lived plasma cell. (781 citations)
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis (678 citations)
- Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. (510 citations)
What are the main themes of his work throughout his whole career to date?
Falk Hiepe spends much of his time researching Immunology, Antibody, Autoantibody, Internal medicine and Lupus erythematosus.
His study in Autoimmunity, Immune system, Plasma cell, Bone marrow and Autoimmune disease falls under the purview of Immunology.
Falk Hiepe combines subjects such as Immunopathology and Antigen with his study of Antibody.
In his research, T cell is intimately related to Flow cytometry, which falls under the overarching field of Autoantibody.
His Internal medicine research includes themes of Gastroenterology and Endocrinology.
His Lupus erythematosus research incorporates elements of Connective tissue disease and B cell.
He most often published in these fields:
- Immunology (69.91%)
- Antibody (34.51%)
- Autoantibody (33.63%)
What were the highlights of his more recent work (between 2017-2021)?
- Immunology (69.91%)
- Antibody (34.51%)
- Internal medicine (28.32%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Immunology, Antibody, Internal medicine, Bone marrow and Autoantibody.
His research on Immunology frequently connects to adjacent areas such as Stem cell.
His Antibody research is multidisciplinary, incorporating elements of Inflammation and Secretion.
The concepts of his Internal medicine study are interwoven with issues in Lupus erythematosus and Oncology.
His work carried out in the field of Bone marrow brings together such families of science as Proteasome inhibitor, Stromal cell and Bortezomib.
Much of his study explores Autoantibody relationship to Systemic lupus erythematosus.
Between 2017 and 2021, his most popular works were:
- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus (197 citations)
- 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus (173 citations)
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial (64 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Immune system
- Antibody
His main research concerns Immunology, Bone marrow, Systemic lupus erythematosus, Internal medicine and Autoantibody.
He has included themes like Proteasome inhibitor, Autoimmunity and Bortezomib in his Bone marrow study.
His Proteasome inhibitor research is multidisciplinary, relying on both Cancer research and Immune system.
His Systemic lupus erythematosus study incorporates themes from CD40, Interferon, B cell, Lupus erythematosus and Molecular biology.
In his study, Randomized controlled trial, Arthritis, Prednisone, Mizoribine and Azathioprine is strongly linked to Placebo, which falls under the umbrella field of Internal medicine.
Antibody covers Falk Hiepe research in Autoantibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
